Development of Polymeric Nanopaclitaxel and Comparison with Free Paclitaxel for Effects on Cell Proliferation of MCF-7 and B16F0 Carcinoma Cells

  • Yadav, Deepak (Drug Standardization Lab, Department of Ilmul-Advia (Pharmacology), Faculty of Medicine) ;
  • Anwar, Mohammad Faiyaz (Department of Chemistry, Hamdard University) ;
  • Garg, Veena (Department of Bioscience and Biotechnology, Banasthali University) ;
  • Kardam, Hemant (Faculty of Science, Hamdard University) ;
  • Beg, Mohd Nadeem (Drug Standardization Lab, Department of Ilmul-Advia (Pharmacology), Faculty of Medicine) ;
  • Suri, Suruchi (Nanomedicine Lab, Faculty of Pharmacy, Hamdard University) ;
  • Gaur, Sikha (Department of Pharmaceutics, PDM College of Pharmacy) ;
  • Asif, Mohd (Drug Standardization Lab, Department of Ilmul-Advia (Pharmacology), Faculty of Medicine)
  • Published : 2014.03.01


Paclitaxel is hydrophobic in nature and is recognized as a highly toxic anticancer drug, showing adverse effects in normal body sites. In this study, we developed a polymeric nano drug carrier for safe delivery of the paclitaxel to the cancer that releases the drug in a sustained manner and reduces side effects. N-isopropylacrylamide/vinyl pyrrolidone (NIPAAm/VP) nanoparticles were synthesized by radical polymerization. Physicochemical characterization of the polymeric nanoparticles was conducted using dynamic light scattering, transmission electron microscopy, scanning electron microscopy and nuclear magnetic resonance, which confirmedpolymerization of formulated nanoparticles. Drug release was assessed using a spectrophotometer and cell viability assays were carried out on the MCF-7 breast cancer and B16F0 skin cancer cell lines. NIPAAm/VP nanoparticles demonstrated a size distribution in the 65-108 nm range and surface charge measured -15.4 mV. SEM showed the nanoparticles to be spherical in shape with a slow drug release of ~70% in PBS at $38^{\circ}C$ over 96 h. Drug loaded nanoparticles were associated with increased viability of MCF-7 and B16F0 cells in comparison to free paclitaxel. Nano loaded paclitaxel shows high therapeutic efficiency by sustained release action for the longer period of time, i increasing its efficacy and biocompatibility for human cancer therapy. Therefore, paclitaxel loaded (NIPAAm/VP) nanoparticles may provide opportunities to expand delivery of the drug for clinical selection.


  1. Trubetskoy VS (1999). Polymeric micelles as carriers of diagnostic agents. Adv Drug Deliv Rev, 37, 81-8.
  2. Surapaneni MS, Das SK, Das NG (2012). Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmaco, 2012, 623139.
  3. Tabar L, Dean PB (2004). Mammography and breast cancer: the new era. Int J Gynaecol Obstet, 82, 319-26.
  4. Verderio P, Bonetti P, Colombo M, Pandolfi L, Prosperi D (2013). Intracellular drug release from curcumin-loaded PLGA nanoparticles induces G2/M block in breast cancer cells. Biomacromole, 14, 672-82.
  5. Verma AK, Chanchal A, Maitra A (2010). Co-polymeric hydrophilic nanospheres for drug delivery: Release kinetics and cellular uptakes. Ind J Exp Bio, 48, 1043-52.
  6. Wang M, Thanou M (2010). Targeting nanoparticles to cancer. Pharmacol Res, 62, 90-9.
  7. Wang YM, Sato H, Adachi I, Hirikoshi I (1996). Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent. Taxol Chem Pharm Bull, 44, 1935-40.
  8. Ward MA, Georgiou TK (2011). Thermoresponsive polymers for biomedical applications. Polymers, 3, 1215-42.
  9. Yang D, Van S, Jiang X, Yu L (2011). Novel free paclitaxel-loaded poly(L-y-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomed, 6, 85-91.
  10. Rfsler A, Vandermeulen GM, Klok HA (2001). Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev, 53, 95-108.
  11. Mashinchian O, Salehi R, Dehghan G, et al (2010). Novel thermosensitivepoly (N-isopropylacrylamide-covinylpyrrolidone-co-methacrylic acid) nanosystems for delivery of natural products. Inter J Drug Del, 2, 278-86.
  12. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63.
  13. Petros RA, DeSimone JM (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov, 9, 615-27.
  14. Rosler A, Vandermeulen GW, Klok HA (2001). Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Del Rev, 53, 95-108.
  15. Sharma A, Straubinger RM (1994). Novel taxol formulations: preparation and characterization of Taxol containing liposomes. Pharm Res, 11, 889-96.
  16. Shroff K, Kokkoli E (2012). PEGylated liposomal doxorubicin targeted to $I{\pm}I^21$-expressing MDA-MB-231 breast cancer cells. Langmuir, 28, 4729-36.
  17. Lerner BH (2001). Breast Cancer Wars. Oxford University Press. New York.
  18. Kikuchi A, Okano T (1998). Biorelated Polymers and Gels. Academic Press, Boston, MA, 1-28.
  19. Kwon GS, Okano T (1996). Polymeric micelles as new drug carriers. Adv Drug Deliv Rev, 21, 107-16.
  20. Lee J, Lee SC, Acharya G, Chang C, Park K (2003). Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res, 20, 1022-30.
  21. Liechty WB, Peppas NA (2012). Expert opinion: Responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm, 80, 241-6.
  22. Ludenberg BB (1997). A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol, 49, 16-21.
  23. Marshall CJ (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signalregulated kinase activation. Cell, 80, 179-85.
  24. Gurses N, Topcul M (2013) The effect of abraxane on cell kinetic parameters of HeLa cells. Asian Pac J Cancer Prev, 14, 4229-33.
  25. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A, 108, 1850-5.
  26. Fonseca C, Simoes S, Gaspar R (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel, 83, 273-86.
  27. Goldspiel BR (1997). Clinical overview of the taxanes. Pharmacothe, 17, 110-25.
  28. Hamidi M, Azadi A, Rafiei P (2008). Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev, 60, 1638-49.
  29. Jabbari E, Yang X, Moeinzadeh S, He X (2013). Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles. Eur J Pharm Biopharm, 84, 49-62.
  30. Jeong B, Bae YH, Kim SW (1999). Thermoreversible gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions. Macromol, 32, 7064-9.
  31. Kataoka K, Harada A, Nagasaki Y (2001). Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev, 47, 113-31.
  32. Deng C, Jiang Y, Cheng R, Meng F, Zhong Z (2012). Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today, 7, 467-480.
  33. Bartoli MH, Boitard M, Fessi H, et al (1990). In vitro and in vivo antitumoral activity of free and encapsulated Taxol. J Microencapsul, 7, 191-7.
  34. Chen DB, Yang TZ, Lu WL, Zhang Q (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing Paclitaxel. Chem Pharm Bull, 49, 1444-7.
  35. Crosasso P, Ceruti M, Brusa P, et al (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Rel, 63, 19-30.

Cited by

  1. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014,
  2. Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles vol.15, pp.23, 2015,
  3. Nanoparticles Promise New Methods to Boost Oncology Outcomes in Breast Cancer vol.16, pp.5, 2015,
  4. Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells vol.16, pp.5, 2015,